Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use Of A Hydroximic Acid Halide Derivative In The Treatment Of Neurodegenerative Diseases

a technology of hydroximic acid and derivatives, applied in the field of n2hydroxy3(1piperidinyl)propoxypyridine1oxide3carboximidoyl chloride in the treatment of neurodegenerative diseases, can solve the problems of slowing and possibly stopping the progress of these diseases, memory loss, language deterioration, impaired visuospatial skills, etc., and achieves the effect of preventing the progressive loss of motoneurons and muscle function

Inactive Publication Date: 2008-02-14
KEMPHARM DENMARK AS
View PDF9 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0036](Dick,J., Greensmith,L. & Vrbova,G. Blocking of NMDA receptors during a critical stage of development reduces the effects of nerve injury at birth on muscles and motoneurones. Neuromuscul. Disord. 5, 371-382 (1995)).
[0057]These results show that following daily treatment of mSOD1(G93A) transgenic mice with compound A (10 mg / kg; i.p.) there is a significant increase in both motor unit and motoneuron survival, as well as an improvement in hind limb muscle function in the later stages of the disease (120 days).

Problems solved by technology

Although great progress has been made in the symptomatic treatment of a number of neurodegenerative disorders, there is still a huge, unmet need for pharmacological and biopharmacological treatments that will slow and possibly halt the progress of these diseases.
AD is characterized by memory loss, language deterioration, impaired visuospatial skills, poor judgment, indifferent attitude, but preserved motor function.
Confusion and restlessness may also occur.
As the disease progresses, the brain produces less and less acetylcholine, and the medications may eventually lose their effect.
Other treatment trials for AD include the Ginko biloba extract—as an antioxidant, but the studies so far do not demonstrate clear efficacy among AD patients.
Nonsteroidal anti-inflammatory agents tested until today did not proved to be effective.
Classically, tremor appears while the individual is at rest and improves with intentional movement; Gradual loss of spontaneous movement, which often leads to a variety of problems such as “freezing”, decreased mental skill or quickness, voice changes, and decrease facial expression; Muscle rigidity, or stiffness of the limbs, occurs in all muscle groups but is most common in the arms, shoulders or neck; Postural instability, or a stooped, flexed posture with bending at the elbows, knees and hips; Gradual loss of automatic movement, including eye blinking and decreased frequency of swallowing; Unsteady walk; Depression and dementia.
Unable to function, the muscles gradually weaken, waste away (atrophy), and twitch (fasciculations).
Eventually, the ability of the brain to start and control voluntary movement is lost.
If not neutralized, free radicals can accumulate and cause random damage to the DNA, membrane lipids and proteins within cells.
Although it is not yet clear how the SOD1 gene mutation leads to motor neuron degeneration, researchers have theorized that an accumulation of free radicals may result from the faulty functioning of this gene.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0031]The following biological tests were carried out with (+)-R—N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride citrate as a test compound. This chemical compound will be referred to as compound A.

[0032]Transgenic mSOD1(G93A) mice of both sexes were used in this study. All experimental animals were treated daily with compound A (10 mg / kg, i.p.) from 35 days of age, following a similar regime to that previously described by Zhu et al 2002 (Zhu,S. et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417, 74-78 (2002)).

[0033]Assessment of muscle function and motor unit number Live, in-vivo electrophysiological assessment of hind limb muscle function was carried out on the extensor digitorum longus (EDL) muscles in both hind limbsto determine the extent of disease progression.Isometric tension recordings and assessment of motor unit number

[0034]Both transgenic animals and their wildtyp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
half relaxation timeaaaaaaaaaa
half relaxation timeaaaaaaaaaa
Login to View More

Abstract

The invention relates to the use of a chemical substance selected from the group consisting of N-′2-hydroxy-3-(1-piperidinyl)-propoxyl !-pyridine-1-oxide-3-carboximidoyl chloride, the optically active enantiomers and the mixtures of enantiomers thereof and pharmaceutically acceptable salts of the racemic and optically active compounds in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases.

Description

TECHNICAL FIELD[0001]The present invention relates to the use of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride in the treatment of neurodegenarative diseases.BACKGROUND ART[0002]it is known, neurodegenerative diseases are progressive, devastating, chronic age related disorders. With increasing life expectancy the incidence of these age-related diseases will be dramatically increasing in the next decades. The treatment of these maladies currently is only symptomatic, causal therapy does not exist due to the largely unknown cause(s) of these multietiological diseases. Though the etiology and the actual localization of cell damage and loss in the central nervous system (CNS) in these disorders—like Alzheimer's disease (AD), Parkinson's disease (PD), Multiple sclerosis (MS), Neuropathies, Huntington's disease (HD), Amyotrophic lateral sclerosis (ALS)—by differ, there are many common points in the disease development, and in the intracellular events.[0...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/4523A61P25/28
CPCA61K31/4545A61P21/02A61P25/00A61P25/14A61P25/16A61P25/28
Inventor GREENSMITH, LINDABURNSTOCK, GEOFFREYURBANICS, RUDOLF
Owner KEMPHARM DENMARK AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products